Noncompliance in cardiovascular clinical trials
Department of Pediatrics
Cardiovascular Diseases; Clinical Trials as Topic; Humans; *Treatment Refusal
Hematology | Oncology | Pediatrics
This article reviews the current literature on attempts to improve compliance and the effect of NC on clinical trials, with a focus on cardiovascular trials (and antiplatelet therapy in particular). Compliance is a major concern for physicians and researchers not only because of its overwhelming financial impact on health care and its potential to undermine clinical outcomes, but also because it poses critical questions about the validity of results from clinical trials. Understanding the implications of NC in practice and research will serve to improve future clinical trial design to accommodate the confounding aspects associated with NC.
DOI of Published Version
Am Heart J. 2005 Nov;150(5):882-6. doi: 10.1016/j.ahj.2005.02.039
American heart journal
Serebruany, Victor L.; Oshrine, Benjamin R.; Malinin, Alex I.; Atar, Dan; Michelson, Alan D.; and Ferguson, James J. III, "Noncompliance in cardiovascular clinical trials" (2005). Hematology/Oncology. 70.